S&P 500   4,626.38 (-0.62%)
DOW   34,888.22 (-0.71%)
QQQ   399.09 (-0.15%)
AAPL   160.00 (-0.15%)
MSFT   335.82 (-0.24%)
FB   335.17 (-0.85%)
GOOGL   2,903.26 (-0.25%)
AMZN   3,574.61 (+0.37%)
TSLA   1,144.40 (+0.65%)
NVDA   332.49 (-0.38%)
BABA   130.12 (-1.13%)
NIO   40.31 (-0.37%)
CGC   10.83 (-2.08%)
AMD   163.74 (+1.13%)
GE   97.13 (-1.29%)
MU   85.77 (-0.43%)
T   23.67 (-0.92%)
F   19.55 (-0.61%)
DIS   146.64 (-0.79%)
ACB   6.38 (-0.93%)
AMC   36.73 (-0.30%)
PFE   52.53 (+0.25%)
BA   196.10 (-1.21%)
S&P 500   4,626.38 (-0.62%)
DOW   34,888.22 (-0.71%)
QQQ   399.09 (-0.15%)
AAPL   160.00 (-0.15%)
MSFT   335.82 (-0.24%)
FB   335.17 (-0.85%)
GOOGL   2,903.26 (-0.25%)
AMZN   3,574.61 (+0.37%)
TSLA   1,144.40 (+0.65%)
NVDA   332.49 (-0.38%)
BABA   130.12 (-1.13%)
NIO   40.31 (-0.37%)
CGC   10.83 (-2.08%)
AMD   163.74 (+1.13%)
GE   97.13 (-1.29%)
MU   85.77 (-0.43%)
T   23.67 (-0.92%)
F   19.55 (-0.61%)
DIS   146.64 (-0.79%)
ACB   6.38 (-0.93%)
AMC   36.73 (-0.30%)
PFE   52.53 (+0.25%)
BA   196.10 (-1.21%)
S&P 500   4,626.38 (-0.62%)
DOW   34,888.22 (-0.71%)
QQQ   399.09 (-0.15%)
AAPL   160.00 (-0.15%)
MSFT   335.82 (-0.24%)
FB   335.17 (-0.85%)
GOOGL   2,903.26 (-0.25%)
AMZN   3,574.61 (+0.37%)
TSLA   1,144.40 (+0.65%)
NVDA   332.49 (-0.38%)
BABA   130.12 (-1.13%)
NIO   40.31 (-0.37%)
CGC   10.83 (-2.08%)
AMD   163.74 (+1.13%)
GE   97.13 (-1.29%)
MU   85.77 (-0.43%)
T   23.67 (-0.92%)
F   19.55 (-0.61%)
DIS   146.64 (-0.79%)
ACB   6.38 (-0.93%)
AMC   36.73 (-0.30%)
PFE   52.53 (+0.25%)
BA   196.10 (-1.21%)
S&P 500   4,626.38 (-0.62%)
DOW   34,888.22 (-0.71%)
QQQ   399.09 (-0.15%)
AAPL   160.00 (-0.15%)
MSFT   335.82 (-0.24%)
FB   335.17 (-0.85%)
GOOGL   2,903.26 (-0.25%)
AMZN   3,574.61 (+0.37%)
TSLA   1,144.40 (+0.65%)
NVDA   332.49 (-0.38%)
BABA   130.12 (-1.13%)
NIO   40.31 (-0.37%)
CGC   10.83 (-2.08%)
AMD   163.74 (+1.13%)
GE   97.13 (-1.29%)
MU   85.77 (-0.43%)
T   23.67 (-0.92%)
F   19.55 (-0.61%)
DIS   146.64 (-0.79%)
ACB   6.38 (-0.93%)
AMC   36.73 (-0.30%)
PFE   52.53 (+0.25%)
BA   196.10 (-1.21%)
NYSE:ENFN

Enfusion Stock Forecast, Price & News

$19.61
+1.46 (+8.04%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.10
$19.90
50-Day Range
N/A
52-Week Range
$17.37
$23.21
Volume
413,578 shs
Average Volume
291,382 shs
Market Capitalization
$2.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive ENFN News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.


Enfusion logo

About Enfusion

Enfusion Inc. is a provider of cloud-based investment management software and services. Through its software, analytics and middle/back-office managed services, it creates enterprise-wide cultures of real-time, data-driven intelligence, boosting agility and powering growth. Enfusion Inc. is based in NEW YORK.

Headlines

Enfusion (NYSE:ENFN) Trading 6.9% Higher
November 29, 2021 |  americanbankingnews.com
Enfusion (NYSE:ENFN) Sets New 12-Month Low at $18.02
November 23, 2021 |  americanbankingnews.com
Enfusion Inc's Quiet Period Will Expire on November 30th (NYSE:ENFN)
November 23, 2021 |  americanbankingnews.com
William Blair Weighs in on Enfusion Inc's FY2021 Earnings (NYSE:ENFN)
November 17, 2021 |  americanbankingnews.com
Enfusion (NYSE:ENFN) Reaches New 1-Year High at $23.10
November 15, 2021 |  americanbankingnews.com
The Goldman Sachs Group Begins Coverage on Enfusion (NYSE:ENFN)
November 15, 2021 |  americanbankingnews.com
Enfusion (NYSE:ENFN) Coverage Initiated by Analysts at William Blair
November 15, 2021 |  americanbankingnews.com
Enfusion (NYSE:ENFN) Research Coverage Started at Piper Sandler
November 15, 2021 |  americanbankingnews.com
Credit Suisse Group Initiates Coverage on Enfusion (NYSE:ENFN)
November 15, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Web
N/A
Phone
N/A
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$2.22 billion
Optionable
Not Optionable

Company Calendar

Today
11/30/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

2.23 out of 5 stars

Computer And Technology Sector

299th out of 891 stocks

Analyst Opinion: 4.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -












Enfusion (NYSE:ENFN) Frequently Asked Questions

Is Enfusion a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Enfusion stock.
View analyst ratings for Enfusion
or view top-rated stocks.

What price target have analysts set for ENFN?

7 Wall Street analysts have issued twelve-month target prices for Enfusion's stock. Their forecasts range from $26.00 to $27.00. On average, they expect Enfusion's stock price to reach $26.25 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price.
View analysts' price targets for Enfusion
or view top-rated stocks among Wall Street analysts.

When did Enfusion IPO?

(ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.

What is Enfusion's stock symbol?

Enfusion trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENFN."

When did the company's quiet period expire?

Enfusion's quiet period expired on Tuesday, November 30th. Enfusion had issued 18,750,000 shares in its public offering on October 21st. The total size of the offering was $318,750,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Enfusion?

Shares of ENFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enfusion's stock price today?

One share of ENFN stock can currently be purchased for approximately $19.61.

How much money does Enfusion make?

Enfusion has a market capitalization of $2.22 billion.

How many employees does Enfusion have?

Enfusion employs 2,021 workers across the globe.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.